<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00725491</url>
  </required_header>
  <id_info>
    <org_study_id>P05703</org_study_id>
    <secondary_id>38651</secondary_id>
    <nct_id>NCT00725491</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Efficacy and Safety of Ganirelix (Orgalutran®) Treatment in Chinese Women Undergoing Controlled Ovarian Stimulation for in Vitro Fertilization (IVF) or Intra Cytoplasmatic Sperm Injection (ICSI) (Study 38651)(P05703)</brief_title>
  <official_title>A Phase III, Multi-center, Open-label, Randomized Study to Assess the Efficacy and Safety of Org 37462 Treatment in Chinese Women Undergoing Controlled Ovarian Stimulation for IVF or ICSI, Using a Long Protocol of Triptorelin as a Reference Treatment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to assess that ganirelix is safe and well-tolerated in
      Chinese women and that a controlled ovarian stimulation (COS) protocol combining recombinant
      follicle stimulating hormone (recFSH) with ganirelix is efficient in Chinese women undergoing
      COS for in vitro fertilization (IVF) or intra cytoplasmatic sperm injection (ICSI).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Amount of International Units (IU) of Recombinant Follicle Stimulating Hormone (recFSH) Needed in a Controlled Ovarian Stimulation (COS) Cycle up to the First Day the Human Chorionic Gonadotropin (hCG) Criterion is Met.</measure>
    <time_frame>At completion of ovarian stimulation; maximally after 18 days of recFSH administration.</time_frame>
    <description>The hCG criterion is met the first day that 3 follicles &gt;= 17 mm are observed.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">259</enrollment>
  <condition>Controlled Ovarian Stimulation</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ganirelix</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>triptorelin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ganirelix</intervention_name>
    <description>On day 6 of recFSH treatment, Org 37462 treatment will start by daily SC administration (0.25 mg) up to and including the day of hCG administration.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Orgalutran®</other_name>
    <other_name>Org 37462</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>triptorelin</intervention_name>
    <description>a daily dose of 0.05 mg SC is to be injected. Triptorelin treatment will start in the luteal phase at day 21-24 of the menstrual cycle. Treatment with recFSH will start 14 days later if treatment with triptorelin has resulted in downregulation, i.e. serum E2 &lt;= 50 pg/ml (&lt;= 200pmol/l). In case the hypogonadotropic state is not reached after 14 days of pretreatment, the dose of triptorelin will be increased to 0.1 mg. If downregulation is not reached within 28 days of pre-treatment with triptorelin, the subject will be discontinued from further hormonal treatment. The daily dose of triptorelin is sustained up to and including the day of hCG.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Decapeptyl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  females of infertile couples for whom COS and IVF or ICSI is indicated

          -  body mass index between 18 and 29 kg/m2

          -  willing and able to give written informed consent.

        Exclusion Criteria:

          -  More than three previous COS cycles for assisted reproduction since last established
             ongoing pregnancy (if applicable)

          -  History of no or low ovarian response to FSH/human menopausal gonadotropin (hMG)
             treatment

          -  Less than 2 ovaries or any other ovarian abnormality including endometrioma

          -  Presence of unilateral or bilateral hydrosalpinx

          -  Any ovarian and/or abdominal abnormality that would interfere with adequate ultrasound
             investigation of at least one ovary

          -  History of or current polycystic ovary syndrome (PCOS)

          -  History of/or current endocrine abnormality

          -  Any clinically relevant hormone value outside the reference range during the early
             follicular phase

          -  Any clinically significant abnormal laboratory value

          -  Hypertension or currently treated hypertension

          -  Recent history of current epilepsy, diabetes, cardiovascular, gastro-intestinal,
             hepatic, renal, pulmonary disease

          -  Alcohol or drug abuse, or history thereof

          -  Current serious allergic symptoms

          -  Abnormal cervical smear

          -  Known hypersensitivity to gonadotropin releasing hormone (GnRH) or its analogs;

          -  Contra-indications for the use of gonadotropins

          -  Use of hormonal preparations within 1 month prior to the date of signing consent;

          -  Administration of any investigational product within 3 months prior to screening.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2008</study_first_submitted>
  <study_first_submitted_qc>July 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2008</study_first_posted>
  <results_first_submitted>December 17, 2009</results_first_submitted>
  <results_first_submitted_qc>December 17, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 22, 2010</results_first_posted>
  <last_update_submitted>November 18, 2014</last_update_submitted>
  <last_update_submitted_qc>November 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Reproductive</keyword>
  <keyword>techniques</keyword>
  <keyword>assisted</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triptorelin Pamoate</mesh_term>
    <mesh_term>Ganirelix</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ganirelix</title>
          <description>0.25 mg once daily from stimulation day 6 onwards up to the day of human chorionic gonadotropin (hCG).</description>
        </group>
        <group group_id="P2">
          <title>Triptorelin</title>
          <description>0.05 mg once daily from cycle day 21-24 onwards up to the day of hCG</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="113">Intent-to-Treat Group</participants>
                <participants group_id="P2" count="120">Intent-to-Treat Group</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="104"/>
                <participants group_id="P2" count="102"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Risk for hyperstimulation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No/too few oocytes/bad quality oocytes</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Fertilization failure</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No/too few embryos/ bad quality embryos</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ganirelix</title>
          <description>0.25 mg once daily from stimulation day 6 onwards up to the day of human chorionic gonadotropin (hCG).</description>
        </group>
        <group group_id="B2">
          <title>Triptorelin</title>
          <description>0.05 mg once daily from cycle day 21-24 onwards up to the day of hCG</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="113"/>
            <count group_id="B2" value="120"/>
            <count group_id="B3" value="233"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Intention to treat population</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.3" spread="2.8"/>
                    <measurement group_id="B2" value="29.1" spread="3.0"/>
                    <measurement group_id="B3" value="29.2" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Intention to treat population</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                    <measurement group_id="B2" value="120"/>
                    <measurement group_id="B3" value="233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>Intention to treat population</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                    <measurement group_id="B2" value="120"/>
                    <measurement group_id="B3" value="233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Amount of International Units (IU) of Recombinant Follicle Stimulating Hormone (recFSH) Needed in a Controlled Ovarian Stimulation (COS) Cycle up to the First Day the Human Chorionic Gonadotropin (hCG) Criterion is Met.</title>
        <description>The hCG criterion is met the first day that 3 follicles &gt;= 17 mm are observed.</description>
        <time_frame>At completion of ovarian stimulation; maximally after 18 days of recFSH administration.</time_frame>
        <population>The number of participants for this analysis included only those participants in the intent-to-treat (ITT) group who received hCG and for whom data was available.</population>
        <group_list>
          <group group_id="O1">
            <title>Ganirelix</title>
            <description>0.25 mg once daily from stimulation day 6 onwards up to the day of human chorionic gonadotropin (hCG).</description>
          </group>
          <group group_id="O2">
            <title>Triptorelin</title>
            <description>0.05 mg once daily from cycle day 21-24 onwards up to the day of hCG</description>
          </group>
        </group_list>
        <measure>
          <title>The Amount of International Units (IU) of Recombinant Follicle Stimulating Hormone (recFSH) Needed in a Controlled Ovarian Stimulation (COS) Cycle up to the First Day the Human Chorionic Gonadotropin (hCG) Criterion is Met.</title>
          <description>The hCG criterion is met the first day that 3 follicles &gt;= 17 mm are observed.</description>
          <population>The number of participants for this analysis included only those participants in the intent-to-treat (ITT) group who received hCG and for whom data was available.</population>
          <units>international units (IU)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1272.0" spread="265.8"/>
                    <measurement group_id="O2" value="1415.6" spread="355.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Whitehead</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>One subject in the ganirelix group started ovarian stimulation with recFSH but was never treated with ganirelix.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ganirelix</title>
          <description>0.25 mg once daily from stimulation day 6 onwards up to the day of human chorionic gonadotropin (hCG).</description>
        </group>
        <group group_id="E2">
          <title>Triptorelin</title>
          <description>0.05 mg once daily from cycle day 21-24 onwards up to the day of hCG</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian hyperstimulation syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="112"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="112"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Antepartum haemorrhage</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="112"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor can review any scientific paper, presentation, or other communication concerning the clinical trial at least 6 weeks ahead of estimated publication or presentation. In order to protect its proprietary interests, the sponsor shall have the right to make its consent, which shall not be withheld unreasonably, conditional upon proper representation of the interpretation of both the sponsor and the investigator(s) in the discussion of the data in such communications.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

